Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCSZ 11

Next Previous
Drug Profile

DCSZ 11

Alternative Names: DCSZ-11

Latest Information Update: 15 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DynamiCure Biotechnology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Complement 1q receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 12 May 2026 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans phase-II trial for Rectal cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease) in USA (IV) in July 2027 (NCT07580339)
  • 07 Oct 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) is underway in South Korea, Taiwan, Australia, USA (IV)(NCT05785754)
  • 02 Jul 2025 West China Hospital plans a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) (NCT07035249)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top